Indus Health Plus launches test to identify genetic risk factors to COVID-19 related parameters
COVIDNAwise test based on studies that show an association between different genetic polymorphisms and the risk of various COVID-19 related parameters
Indus Health Plus launched COVIDNAwise, an add on package bought along with DNAwise 2.0 package, under which patients will receive a separate report regarding genetic risks of about 18 parameters under three categories – Susceptibility and Severity of COVID-19, Nutrition & COVID-19, and Co-morbidities of COVID-19.
While the cost of the saliva-based DNAwise 2.0 launched this June is Rs 14,999 + 18 per cent GST, the add on COVIDNAwise package is at Rs 4999 + 18% GST.
According to a release, Indus Health Plus came up with the COVIDNAwise test based on studies that show an association between different genetic polymorphisms and the risk of various COVID-19 related parameters.
While exposure to the SARS-Cov-2 virus remains the most critical factor determining the chances of getting COVID-19, the release points out that other risk factors may influence the response to infection. These risk factors include reduced immunity, presence of existing health conditions (comorbidities), old age, and gender (males being more susceptible than females).
Moreover, the genetic variants can influence the response to COVID-19 by modulating the immune function that can make an individual less or more susceptible than others. Therefore, the COVIDNAwise test will help in decoding the genetic makeup and informing an individual about their genetic susceptibility and genetic risk for severe complications associated with COVID-19 like respiratory failure etc. (severity) of COVID-19.
Besides, it will reportedly enable the understanding of the genetic risk of deficiency of various nutrients that are immunity boosters and catalysers for good metabolism to fight the infection. Apart from that, it will also accentuate the comorbidities like diabetes, obesity, hypertension, etc. that can aggravate the severity of COVID-19 infection.